Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
GSK buys US biopharma company Nuvalent for $10.6B
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. |…
British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company…
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma…
GSK is acquiring Nuvalent for $10.6 billion in cash, gaining three late-stage lung cancer therapies including two drugs already…
